Standard BioTools Inc. Proceeds from Issuance of Convertible Preferred Stock
Standard BioTools Inc. (LAB) reported Proceeds from Issuance of Convertible Preferred Stock of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-01.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock · last filed 2025-03-11
- Standard BioTools Inc. proceeds from issuance of convertible preferred stock for the quarter ending 2023-12-31 was $0.00.
- Standard BioTools Inc. proceeds from issuance of convertible preferred stock for the quarter ending 2023-09-30 was $0.00.
- Standard BioTools Inc. proceeds from issuance of convertible preferred stock for the quarter ending 2022-12-31 was $0.00.
- Standard BioTools Inc. proceeds from issuance of convertible preferred stock for the quarter ending 2022-09-30 was $0.00.
- Standard BioTools Inc. proceeds from issuance of convertible preferred stock for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- Standard BioTools Inc. proceeds from issuance of convertible preferred stock for fiscal 2022 was $225.00M.
- Standard BioTools Inc. proceeds from issuance of convertible preferred stock for fiscal 2021 was $0.00.
- Standard BioTools Inc. proceeds from issuance of convertible preferred stock for fiscal 2011 was $0.00.
| Period end | Proceeds from Issuance of Convertible Preferred Stock 3 month | Proceeds from Issuance of Convertible Preferred Stock 6 month | Proceeds from Issuance of Convertible Preferred Stock 9 month | Proceeds from Issuance of Convertible Preferred Stock 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | $0.00 derived: sum of 2 quarters · filed 2024-03-01 | $0.00 10-K · filed 2024-03-01 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $0.00 10-Q · filed 2023-11-07 | ||
| 2023-06-30 | $0.00 10-Q · filed 2023-08-08 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $0.00 derived: sum of 2 quarters · filed 2025-03-11 | $225.00M 10-K · filed 2025-03-11 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $225.00M 10-Q · filed 2023-11-07 | ||
| 2022-06-30 | $225.00M 10-Q · filed 2023-08-08 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | $0.00 derived: sum of 2 quarters · filed 2023-03-14 | $0.00 10-K · filed 2023-03-14 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $0.00 10-Q · filed 2022-11-09 | ||
| 2021-06-30 | $0.00 10-Q · filed 2022-08-09 | |||
| 2011-12-31 | $0.00 10-K · filed 2012-03-26 | |||
| 2010-12-31 | $0.00 10-K · filed 2012-03-26 | |||
| 2009-12-31 | $7.41M 10-K · filed 2012-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |